Comparison between flecainide and ajmaline challenge in Brugada syndrome patients

Vincent Probst(Centre National de la Recherche Scientifique), Hervé Le Marec(Centre National de la Recherche Scientifique), Dominique Babuty(Université de Tours), Jacques Mansourati(Université de Bretagne Occidentale), Stéphanie Chatel(Centre National de la Recherche Scientifique), Frédéric Sacher(Centre Hospitalier Universitaire de Bordeaux), P. Mabo(Hôpital Pontchaillou), Jean‐Baptiste Gourraud(Centre Hospitalier Universitaire de Nantes)
European Heart Journal
August 2, 2013
10.1093/eurheartj/eht308.p2295
Cited by 2

Related Papers

HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies
|Heart Rhythm|2011|1.5k
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death
|Nature|2003|961
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)
|EP Europace|2011|904
Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome
|Circulation|2010|850
Cardiac conduction defects associate with mutations in SCN5A
|Nature Genetics|1999|638